 |
|
 |
|
|
|
 What is RSS?
Conflict of interests halt Seroxat inquiry
A Government inquiry into the safety of the SSRI class of antidepressants has been scrapped and must start again from scratch after potential conflicts of interest were uncovered...(more)
Former ImClone chief fined $800,000 for insider dealing
Former ImClone boss Samuel Waksal has agreed to pay $800,000 to settle some of the charges brought against him by the US Securities & Exchange Commission...(more)
Humanitarian disaster looms in Iraq
Fears of a humanitarian crisis in Iraq are growing as civilians are forced to flee or stay in the heavily bombarded cities of Basra and Baghdad...(more)
British Biotech takes 'first step' on acquisition trail
British Biotech has agreed a merger with RiboTargets in what could be the first of several acquisitions...(more)
GSK claims victory in US parallel import row
GlaxoSmithKline has claimed victory in its controversial bid to block parallel imports of its drugs from Canada into the US...(more)
Research body management draws criticism
MPs have accused the UK largest public funder of medical research of poor decision-making and financial mismanagement...(more)
GSK international pharma chief leaves for Chiron
GlaxoSmithKline head of international pharmaceutical operations, Howard Pien, is to leave the company to become Chief Executive of Chiron...(more)
Pfizer/Pharmacia mega-merger gains final clearance
The creation of a new pharmaceutical goliath is now just days away after Pfizer and Pharmacia received final regulatory clearance for their merger...(more)
Celltech takes 10% stake in OGS
The battle to buy Oxford GlycoSciences has intensified following the acquisition of a 10% stake in the company by Celltech...(more)
Betaferon and Avonex in head-to-head MS trial
Schering AG is to launch the largest ever therapeutic multiple sclerosis trial, comparing its drug Betaferon with Biogen's rival Avonex...(more)
Government to limit pharmacy reform
The Government has signalled it will limit the recommended de-regulation of pharmacies, after warnings that 6,000 community pharmacies could go out of business...(more)
Clinicians are the new NHS bureaucrats
New bodies intended to allow doctors and nurses to cut through red tape and re-build services around the patient have added to NHS bureaucracy and are stifling faster reform...(more)
First new HIV drug in seven years gets approval
The first novel HIV treatment in seven years, Roche Fuzeon, is to undergo fast track approval in the US...(more)
Miscalculation throws GP contract into crisis
The fate of the new GP contract is hanging in the balance after doctors claim to have found a massive miscalculation that would see them worse off under the new agreement...(more)
CellFactors secures £1.1m
UK cell therapy company CellFactors has made progress in its fundraising efforts as it seeks to secure a short-term revenue stream...(more)
Elan sues King Pharma over drug sales
Elan is taking legal action to force King Pharmaceuticals to buy two drugs it urgently needs to divest to help tackle debts of $1.3 billion...(more)
OGS withdraws CAT offer recommendation
Oxford GlycoSciences has withdrawn its support of Cambridge Antibody Technology's £110 million all-share bid for the company, despite believing a merger with its rival is in shareholders' best interests...(more)
Generic threat to Lilly's biggest seller
A court challenge to Eli Lilly's patent on its number one drug Zyprexa could spell serious trouble for the company, still recovering from a generic onslaught against former blockbuster Prozac...(more)
Shire appoints Emmens as new chief executive
Matthew Emmens, former head of Merck KGaA's global prescription group, has been appointed as the new Chief Executive of Shire Pharmaceuticals...(more)
Germany delay undermines Crestor confidence
AstraZeneca's cholesterol treatment Crestor has been dealt a serious blow following Germany's withdrawal from a pan-European approval process...(more)
Smallpox vaccine puts Acambis into profit
Vaccine company Acambis has joined rivals PowderJect and Celltech in the elite group of profitable UK biotech companies...(more)
Smallpox vaccine puts Acambis into profit
Vaccine company Acambis has joined rivals PowderJect and Celltech in the elite group of profitable UK biotech companies...(more)
US healthcare 'in danger of collapse'
The US healthcare system in danger of collapse..(more)
Parliamentary showdown for foundation trust plans
Health Secretary Alan Milburn has published the final plans for the controversial foundation trusts with the promise that all NHS hospitals could become self-governing within four or five years...(more)
Generic threat to Lilly's biggest seller
A court challenge to Eli Lilly's patent on its number one drug Zyprexa could spell serious trouble for the company, still recovering from a generic onslaught against former blockbuster Prozac...(more)
Parliamentary showdown for foundation trust plans
Health Secretary Alan Milburn has published the final plans for the controversial foundation trusts with the promise that all NHS hospitals could become self-governing within four or five years..(more)
Industry reputation under fire at home and abroad
Continuing conflict over access to medicines in developing countries and growing distrust of big pharma in domestic markets is threatening to irreparably damage the industry's reputation...(more)
BMS attempts to distance itself from fraud allegations
Bristol-Myers Squibb is attempting to draw a line under allegations of fraud and financial misconduct by downgrading earnings as far back as 1999...(more)
Staff shortages holding back NHS progress
A chronic shortage of staff in some parts of the NHS is holding back improvements to the service, according to a major new report...(more)
Levitra brings three dimensions to ED market
Bayer and GlaxoSmithKline's new erectile dysfunction treatment Levitra has been launched in the UK, its first market after receiving European marketing authorisation...(more)
Novartis buys Pfizer incontinence drug
Novartis has bought Pfizer's incontinence product Enablex ahead of the US giant's merger with Pharmacia...(more)
GSK in running for Pfizer incontinence drug
GlaxoSmithKline has been tipped to buy a potential blockbuster incontinence drug from Pfizer ahead of the US company's merger with Pharmacia...(more)
Trusts warned over fixing waiting times
All NHS trusts will have to review how they report waiting times after a spot check found widespread distortion and fiddling of figures...(more)
Consultants threaten to quit
More than a quarter of hospital consultants are ready to resign or retire from the NHS if they don¿t receive a satisfactory contract...(more)
Crestor goes head-to-head with Lipitor
AstraZeneca's much anticipated statin Crestor is to go head-to-head on price with Pfizer blockbuster Lipitor in the Netherlands...(more)
GSK launches prostate drug
GlaxoSmithKline is to launch Avodart, a new treatment for enlarged prostates, next week into a crowded $1.6 billion global market...(more)
Industry lukewarm on new labelling guidelines
New guidelines on the labelling of medicines have received a cautious welcome from the pharma industry...(more)
Milburn defiant in face of foundation trust revolt
Health Secretary Alan Milburn has been in defiant mood as opposition to his plans to set up autonomous foundation trusts grows..(more)
Paxil patent blow for GSK
GlaxoSmithKline has been defeated in a vital US court case that could lead to a generic version of Paxil being introduced as early as September...(more)
|
|
|
|
|
|
|
|
|
|
|
